Medicine
Opvee 2.7 mg/100 ul nasal spray
Opvee 2.7 mg/100 ul nasal spray is a prescription medicine containing Nalmefene for nasal use, marketed by Indivior, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store OPVEE nasal spray at controlled room temperature 15°C to…
Key facts
- Active ingredient (INN)
- Nalmefene
- Brand
- Opvee
- Strength
- 2.7 mg/100 ul
- Dosage form
- Nasal spray
- Route
- Nasal
- Packs
- 2 blister pack
- Marketing authorisation holder
- Indivior
- Manufacturer
- Indivior
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store OPVEE nasal spray at controlled room temperature 15°C to 25°C (59°F to 77°F). Short-term excursions permitted between 4°C to 40°C (39°F to 104°F). Store OPVEE nasal spray in the blister and cartons provided. Protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- N07BB05 Nalmefene
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 2 October 2023
- Identifiers
- RxCUI 2639721, 2639727DailyMed set ID 999a4269-9e54-4801-b2ac-2a7276f0b94fNDC 12496-0003Application NDA217470
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 2 blister pack in 1 carton / 1 vial, single-dose in 1 blister pack / 100 ul in 1 vial, single-dose | 12496-0003-2 | Indivior | 2 October 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Nalmefene
Clinical summary
Nalmefene is an opioid antagonist indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, among other approved uses. MedsAcross supplies Nalmefene for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about NalmefeneFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- OPVEE prescribing information (Indivior) · U.S. National Library of Medicine, DailyMed
- Selincro: European public assessment report (EPAR) · European Medicines Agency
Need Opvee 2.7 mg/100 ul nasal spray for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.